Monoclonal Antibody vs FcRn Antagonist — Immunology Deal Terms Comparison
Market Analysis
In immunology, Monoclonal Antibody and FcRn Antagonist represent two of the most actively transacted modalities. At Phase 2, Monoclonal Antibody deals carry a median total deal value of $2.5B with $480M upfront, compared to $3.0B total value and $583M upfront for FcRn Antagonist. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Monoclonal Antibody development milestones average $405M versus $491M for FcRn Antagonist. Commercial milestones are $911M for Monoclonal Antibody and $1.1B for FcRn Antagonist. Royalty rates range from 13.2%-22.1% for Monoclonal Antibody and 14%-23.4% for FcRn Antagonist.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Monoclonal Antibody and FcRn Antagonist deal terms compare in immunology?
Which modality commands higher royalty rates: Monoclonal Antibody or FcRn Antagonist?
How do milestone structures differ between Monoclonal Antibody and FcRn Antagonist?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.